Welcome to our dedicated page for AUTOLUS THERAPEUTICS news (Ticker: AUTL), a resource for investors and traders seeking the latest updates and insights on AUTOLUS THERAPEUTICS stock.
Autolus Therapeutics plc reports news on its commercial-stage biopharmaceutical business developing, manufacturing and delivering next-generation programmed T cell therapies. Updates center on AUCATZYL (obecabtagene autoleucel, or obe-cel), product revenue, manufacturing capacity, gross margin plans and the company’s acute lymphoblastic leukemia business.
Company announcements also cover clinical programs using obe-cel and related T cell therapy candidates in pediatric relapsed/refractory acute lymphoblastic leukemia, lupus nephritis and progressive multiple sclerosis. Other recurring items include financial results, operational efficiency actions, investor presentations, Nasdaq inducement equity grants and ADR-related public-company disclosures.
Autolus Therapeutics (NASDAQ: AUTL) announced the initiation of its pivotal Phase 1b/2 AUTO1-AL1 study for adult patients with relapsed/refractory acute lymphoblastic leukemia (ALL). As of May 13, 2020, AUTO1 demonstrated a favorable safety profile, achieving an 84% MRD-negative complete response (CR) in 19 patients. Notably, event-free survival at 6 months was 62%, with overall survival at 72%. Meanwhile, progress on AUTO3 suggests potential use in outpatient settings. The company will discuss EHA data in a conference call on June 12, 2020.
Autolus Therapeutics plc (Nasdaq: AUTL) has rescheduled its investor conference call to discuss data from the European Hematology Association EHA25 Virtual Congress to June 12, 2020, at 7:30 am EDT. Previously set for June 15, the call will feature Dr. Christian Itin and the AUTO1 and AUTO3 clinical teams discussing CAR T cell therapies targeting adult Acute Lymphocytic Leukemia and relapsed/refractory Diffuse Large B Cell Lymphoma. Investors can join via a dial-in or webcast, with a replay available afterward.
Autolus Therapeutics (AUTL) has announced its Annual General Meeting (AGM) scheduled for June 18, 2020, at its headquarters in White City. Due to UK government Stay at Home Measures amid the coronavirus pandemic, only two shareholders will attend in person, and the meeting will not have a webcast. Shareholders are urged to vote via proxy ahead of the meeting, as in-person voting is not permitted this year. Results of the poll votes will be communicated through a subsequent press release. Autolus focuses on developing innovative programmed T cell therapies for cancer treatment.
Autolus Therapeutics plc (Nasdaq: AUTL) announced new preclinical data on its programmed T cell therapies at the AACR Virtual Annual Meeting II, scheduled for June 22-24, 2020. Key presentations include AUTO5 targeting T cell lymphoma, AUTO6NG for small cell lung cancer, and AUTO7 for advanced prostate cancer. Oral and poster presentations will showcase the advancements and efficacy of these therapies. A conference call to discuss the findings will be held on June 25, 2020, at 8:30 am EDT. These developments highlight Autolus's commitment to innovative cancer treatments.
Summary not available.